On 01-28-2k21 (Thursday) Shareholders tracking shares of Adamis Pharmaceuticals Corporation (ADMP) belongs to Healthcare sector and Drug Manufacturers – Specialty & Generic industry. ADMP flaunted -17.68% to reach at $1.35 during previous trading session. ADMP Inc. has a total market value of 89.67M at the time of writing – representing $93.66M outstanding shares. Turning to other widely-considered trading data, this company’s half yearly performance is observed at 22.17%.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients. Preliminary data from that study shows that Tempol decreases cytokines from stimulated cells from COVID-19 patients. The collaboration expects to submit the final data to a peer reviewed journal.
Tempol has previously demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. Both inflammatory cytokines and reactive oxygen species (ROS) from cells of the immune system called macrophages and neutrophils damage the lung in Acute Respiratory Distress Syndrome (ARDS). In animal models, Tempol has been shown to decrease proinflammatory cytokines (cytokine storm), and through its potent antioxidant activity has been shown to decrease the harmful effects of ROS. In addition, Tempol has been shown to decrease platelet aggregation, a problem observed in many COVID-19 patients. Numerous published articles describing animal models of ARDS show Tempol to cause a decrease in lung inflammation and preserve lung pathology associated with acute and chronic lung injury. To this end, Tempol has been shown to decrease the genes (HIF-la and HIF-2a) associated with hypoxia. Hypoxia is a key indicator often associated with severe disease and a poor outcome. Controlling hypoxia and the cytokine storm can be considered essential to the successful treatment of COVID-19. Tempol could potentially be used to treat the many manifestations of COVID-19 and prevent severe disease as well as the need for hospitalization.
Dr. Dennis J. Carlo, President and CEO of Adamis commented: “We are very excited about the collaboration with Stanford University. This is the first data that we know of that shows Tempol has a positive impact in decreasing cytokine production from COVID-19 positive patient cells. These data further support the need for clinical studies of Tempol in COVID-19 patients. We intend to continue pursuing government and/or non-government funding for these studies; however, the recent exercise of outstanding warrants have provided the company with additional capital which may be used to help support and/or accelerate Tempol clinical studies.”
The USA listed company saw a recent price trade of $1.35 and 23,788,266 shares have traded hands in the session. There are 15.78M shares which are traded as an average over the last three months period.
Many investors forget that one of the defining characteristics of the stock market is that it’s a market. Buyers and sellers help determine the price of each stock, and the more buyers and sellers a particular stock has interested in it, the more liquid the market will be. Liquidity can have a profound impact on just how violently stock prices can move in either direction, and the reasons have to do with the nature of the market in a stock’s shares.
Trading volume, or volume, is the number of shares or contracts that indicates the overall activity of a security or market for a given period. Trading volume is an important technical indicator an investor uses to confirm a trend or trend reversal. Volume gives an investor an idea of the price action of a security and whether they should buy or sell the security.
Looking performance record on shares of Adamis Pharmaceuticals Corporation (ADMP) we observed that the stock has seen a move 96.94% over the last 52-week trading period. The stock generated performance of 69.13% tracking last 3 months. Investors will be anxiously watching to see if things will turn around and the stock will start gaining or losing momentum over the next few months. If we look back year-to-date, the stock has performed 178.29%. Shares are at -5.59% over the previous week and 160.62% over the past month.
Fluctuating the focus to what the Wall Street analysts are projecting, we can see that the current consensus target price on shares is $1.00. Analysts often put in a lot of work to study stocks that they cover. Wall Street analysts have a consensus recommendation of 3.00on this stock. This number falls on a one to five scale where a 1 would be considered a strong buy and 5 means a strong sell, 2 shows Buy, 3 Hold, 4 reveals Sell recommendation.
Watching some historical volatility numbers on shares of Adamis Pharmaceuticals Corporation (ADMP) we can see that the 30 days volatility is presently 15.80%. The 7 days volatility is 19.47%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.
The company has a beta of 1.87. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.
The Average True Range (ATR) value reported at 0.22. The average true range (ATR) is a technical analysis indicator that measures volatility by decomposing the entire range of an asset price for that period. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. The ATR may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. It was created to allow traders to more accurately measure the daily volatility of an asset by using simple calculations. The indicator does not indicate the price direction; rather it is used primarily to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.
Adamis Pharmaceuticals Corporation (ADMP) stock positioned 94.62% distance from the 200-day MA and stock price situated 109.14% away from the 50-day MA while located 53.05% off of the 20-day MA.
RSI value sited with reading of 54.55. Relative Strength Index (RSI) is an extremely useful and popular momentum oscillator. The RSI compares the magnitude of a stock’s recent gains to the magnitude of its recent losses and turns that information into a number that ranges from 0 to 100. It takes a single parameter, the number of time periods to use in the calculation. In his book, Wilder recommends using 14 periods.
Observing the Technical Indicators:
Adamis Pharmaceuticals Corporation institutional ownership is held at 7.10% while insider ownership was 1.30%. As of now, ADMP has a P/S, P/E and P/B values of 4.87, 0 and 3.75 respectively. Its P/Cash is valued at 7.23. The Company’s net profit margin for the 12 months at 0. Comparatively, the gazes have a Gross margin 12.00%.
Looking into the profitability ratios of ADMP stock, an investor will find its ROE, ROA, ROI standing at -115.90%, -78.50% and -76.90%, respectively.
Earnings per Share Details of Adamis Pharmaceuticals Corporation:
The EPS of ADMP is strolling at -0.50, measuring its EPS growth this year at 44.90%. As a result, the company has an EPS growth of 0 for the approaching year.
Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.
The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.